8-K: ZyVersa Therapeutics Secures $2 Million in Private Placement to Bolster Working Capital

ZyVersa Therapeutics raises $2 million through a private placement of pre-funded and common stock purchase warrants to enhance its working capital.

Summary

• ZyVersa Therapeutics, Inc. has entered into a Securities Purchase Agreement with an institutional accredited investor for a private placement.
• The company will issue pre-funded warrants to purchase up to 2,105,265 shares of common stock and Series A-3 common stock purchase warrants to purchase an additional 2,105,265 shares.
• The purchase price for each pre-funded warrant was $0.9499.
• The private placement closed on March 7, 2025, with gross proceeds of approximately $2 million before deducting fees and expenses.
• Net proceeds will be used for working capital purposes.
• Each pre-funded warrant has an exercise price of $0.0001 per share and is immediately exercisable.
• Each common warrant has an exercise price of $1.00 per share and is exercisable upon stockholder approval, expiring five years from the approval date.
• The company has agreed to file a registration statement to register the resale of the warrant shares within 10 calendar days of filing its Annual Report on Form 10-K for the year ended December 31, 2024.
• The company engaged A.G.P./Alliance Global Partners as the placement agent, with a cash fee of 6.5% of the gross proceeds plus reimbursement of certain expenses.
• Directors and executive officers have entered into lock-up agreements restricting the sale of common stock and common stock equivalents for 15 days after the effectiveness of the registration statement.
• The company also amended existing common share purchase warrants to reduce the exercise price to $1.00 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, it is doing so through a dilutive private placement. The terms of the placement appear to be reasonable, but the overall impact on existing shareholders is uncertain.

Positives

• The private placement provides ZyVersa Therapeutics with $2 million in gross proceeds to bolster its working capital.
• The pre-funded warrants offer immediate exercisability, potentially providing the company with additional capital in the near term.
• The lock-up agreements with directors and executive officers demonstrate commitment and alignment with the company's success.
• The amendment of existing warrants to a lower exercise price may incentivize earlier exercise, providing additional capital.

Negatives

• The private placement involves the issuance of warrants, which could dilute existing shareholders if exercised.
• The company is restricted from issuing certain securities for a period of time, which could limit its financing options.
• The company is paying a cash fee of 6.5% of the gross proceeds to the placement agent, which reduces the net proceeds available for working capital.

Risks

• The company's ability to use the net proceeds effectively for working capital purposes is crucial for its future success.
• The company's reliance on future stockholder approval for the common warrants introduces uncertainty.
• The company's compliance with the terms of the warrants and the purchase agreement is essential to avoid potential penalties and legal issues.
• The company's ability to meet the filing and effectiveness deadlines for the registration statement is critical to provide liquidity for investors.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital purposes and will file a registration statement to register the resale of the warrant shares.

Management Comments

• The document does not contain direct quotes from management, but it outlines actions taken by the company's officers and directors.

Industry Context

Private placements are a common method for small-cap companies like ZyVersa Therapeutics to raise capital without the expense and time commitment of a public offering. The use of warrants is also a typical feature to attract investors in such placements.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as [Hypothetical Biotech Company A] and [Hypothetical Biotech Company B], have also utilized private placements with warrants to fund their operations.
• The terms of this private placement, including the warrant coverage and exercise prices, appear to be within the typical range for similar transactions in the current market environment.
• The placement agent fee of 6.5% is also within the range of fees charged by placement agents for similar transactions.
• The lock-up agreements with directors and executive officers are a standard practice to demonstrate commitment and stability to investors.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• Employees may benefit from the increased working capital, which could support job security and growth.
• Customers may benefit from the company's ability to continue operations and develop new products.
• Suppliers may benefit from the company's ability to pay its bills and continue purchasing supplies.
• Creditors may benefit from the company's improved financial stability.

Next Steps

• The company needs to file a registration statement to register the resale of the warrant shares.
• The company needs to seek stockholder approval for the issuance of the common warrant shares.
• The company needs to effectively utilize the net proceeds for working capital purposes.

Key Dates

Keywords

private placement, warrants, pre-funded warrants, common stock, working capital, securities purchase agreement, institutional investor, registration statement, placement agent, lock-up agreement, exercise price, dilution